A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement-Reference-Cited by-同舟云学术

A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement

Published:2022-10-07 Issue:1 Volume:30 Page:193-202
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ikenaga Naoki,Miyasaka Yoshihiro,Ohtsuka Takao,Nakata Kohei,Adachi Tomohiko,Eguchi Susumu,Nishihara Kazuyoshi,Inomata Masafumi,Kurahara Hiroshi,Hisaka Toru,Baba Hideo,Nagano Hiroaki,Ueki Toshiharu,Noshiro Hirokazu,Tokunaga Shoji,Ishigami Kousei,Nakamura Masafumi^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-12566-1.pdf

Reference38 articles.

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

2. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833–46.

3. Japan Pancreas Society. General Rules for the Study of Pancreatic Cancer. 7th edn. Tokyo: Kanehara; 2016.

4. Kato H, Usui M, Isaji S, et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20:601–10.

5. Murakami Y, Satoi S, Sho M, et al. National Comprehensive Cancer Network resectability status for pancreatic carcinoma predicts overall survival. World J Surg. 2015;39:2306–14.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma;The American Surgeon™;2024-04-18

2. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma;American Journal of Clinical Oncology;2023-12-22

3. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety;Biomedicines;2023-07-15

4. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study;International Journal of Surgery;2023-07-06

5. Hot topics in pancreatic cancer management;World Journal of Gastrointestinal Surgery;2023-02-27